Hims & Hers Health Inc. (HIMS) experienced a significant pre-market plunge of 7.16% on Tuesday, extending losses from after-hours trading following the release of its fourth-quarter and full-year 2025 financial results.

The decline is attributed to a mixed earnings report where the company's Q4 revenue of $617.8 million slightly missed analyst estimates, while earnings per share beat expectations. More critically, the company issued first-quarter 2026 revenue guidance of $600 million to $625 million, which fell substantially short of Wall Street forecasts, casting doubt on near-term growth prospects.

Adding to investor concerns, regulatory filings highlighted uncertainty regarding potential actions by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS), or Department of Justice (DOJ) concerning the marketing of compounded GLP-1 products, a treatment area the company is involved in. The company also faces profit pressure from spending on a Super Bowl advertisement and planned investments in new technology and product rollouts, contributing to the sell-off.